eTheRNA research agreement with Merck to access mRNA technologies 

eTheRNA immunotherapies has partnered with Merck to investigate the application of eTheRNA’s mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. 


The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases.  

The collaboration 

With this collaboration, eTheRNA and Merck will assess the feasibility of using eTheRNA’s mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease. If successful, mRNAs encoding antigens nominated by Merck and directly relevant for human diseases will then be designed and evaluated preclinically. 

Official comment 

Steven Powell, the CEO of eTheRNA, said: “We are extremely pleased to sign this partnership agreement with Merck, a leading German science and technology company. As two companies committed to innovation and creating patient focused solutions, we are excited about the many advantages such a partnership can offer to improve patient care and address a significant market need”. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free